

Eighth Annual Report 1999

Creutzfeldt-Jakob Disease Surveillance in the UK

The National CJD Surveillance Unit
Western General Hospital
Edinburgh EH4 2XU

www.cjd.ed.ac.uk

Dept of Infectious and Tropical Diseases
London School of Hygiene and Tropical Medicine
Keppel Street, London WC1E 7HT

CONTENTS

	Page
Section 1 Summary	3
Section 2 Clinical Surveillance	5
Section 3 Case-Control Study	22
Section 4 Neuropathology	27
Section 5 Publications	37
Section 6 Staff	53

SECTION**1*****Summary***

The national surveillance programme for Creutzfeldt-Jakob disease (CJD) in the UK was initiated in May 1990. In 1999, the National CJD Surveillance Unit (NCJDSU) became a WHO Collaborative Centre for Reference and Research on the Surveillance and Epidemiology of Human Transmissible Spongiform Encephalopathies (TSEs). The information provided in this eighth report continues to provide evidence of a high level of case ascertainment. Detailed clinical and epidemiological information has been obtained for the great majority of patients. A high post mortem rate has been maintained through the period of the study 1990-1999. The success of the project continues to depend on the extraordinary level of co-operation from the neuroscience community and other medical and paramedical staff throughout the UK. We are particularly grateful to the relatives of patients for their help with this study.

The average number of cases of sporadic CJD identified annually since 1990 was higher than in previous surveillance periods extending back to 1970. It is impossible to say with certainty to what extent these changes reflect an improvement in case ascertainment and to what extent, if any, they reflect changes in incidence.

In 1990-1999 mortality rates from sporadic CJD in England, Scotland and Wales were, respectively, 0.74, 0.89 and 1.03/million/year. These rates are comparable to those observed in other countries in Europe and elsewhere in the world, including countries which are free of BSE. Mortality from sporadic CJD in Northern Ireland was lower (0.44/million/year). This difference is not statistically significant. There was some variation in the rates between the different regions within the UK but this variation is not statistically significant. The highest mortality from sporadic CJD was observed in the East Anglia region of England (SMR=129 [compared to the highest mortality rate of 126 in the South West in the last report]). Previous analyses have found no convincing evidence of space-time clustering, and this remains the case for the analyses in this report.

Up until 31 December 1999, there have been 51 deaths from variant CJD (vCJD) in the UK (and one further case was confirmed in January 2000). In 50 of these 52 cases the diagnosis has been confirmed neuropathologically. The clinical and neuropathological features of all these cases of vCJD are remarkably uniform and consistent with previous descriptions^{1,2,3}. Statistical analysis has provided no evidence of space-time clustering of cases of vCJD nor that the rate of occurrence of new cases has increased with time since 1994.

Analysis of the incidence of vCJD by standard region suggests that the incidence of vCJD in the "North" of the UK may be higher than in the "South" ($p=0.02$). The possibility that this finding is due to more efficient case ascertainment in the "North" is not supported by analyses which reveal no difference in the incidence of sporadic CJD between "North" and "South". Further analyses are being undertaken to determine whether there may be differences in the regional exposure to putative risk factors for vCJD, including dietary exposures. However, the apparent differential incidence of vCJD between "North" and "South" should be treated with caution in view of the absence of an *a priori* hypothesis and the small numbers of cases on which this finding is based.

Risk factors for the development of vCJD include age, residence in the UK and methionine homozygosity at codon 129 of the prion protein gene - 49 cases of vCJD with available genetic analysis have all been methionine homozygotes. The analyses in this report do not provide evidence to suggest that there is an increased risk of vCJD associated with past surgery, previous blood transfusion, occupation or a range of dietary factors. However, the power of the case-control study, from which these results are derived, is limited by the small number of cases and controls. For some putative risk factors, such as blood transfusion or surgery, it will be many years before an accurate assessment of risk can be made because of the likely prolonged incubation periods.

¹ Zeidler M, Johnstone EC, Bamber RWK, Dickens CM, Fisher CJ, Francis AF, Goldbeck R, Higgs R, Johnson-Sabine EC, Lodge GJ, McGarry P, Mitchell S, Tarlo L, Turner M, Ryley P, Will RG. New variant Creutzfeldt-Jakob disease: psychiatric features. *Lancet* 1997; 350: 908-910.

² Zeidler M, Stewart GE, Barraclough CR, Bateman DE, Bates D, Burn DJ, Colchester AC, Durward W, Fletcher NA, Hawkins SA, Mackenzie JM, Will RG. New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests. *Lancet* 1997; 350: 903-907.

³ Ironside JW. New-variant Creutzfeldt-Jakob disease. *Neuropathology* 1998; 18(2): 131-138.

SECTION**2****2. Clinical Surveillance**

The national surveillance of CJD was initiated in May 1990 in response to a recommendation in the Report of the Working Party on Bovine Spongiform Encephalopathy (Southwood Committee). The surveillance is funded by the Department of Health and by the Scottish Executive Health Department. The initial aim of the project was to identify any change in the pattern of CJD that might be attributable to the emergence of bovine spongiform encephalopathy (BSE). Such a change was recognised in 1996 when vCJD was first described. The project now aims to monitor the characteristics of all forms of CJD, to identify trends in incidence rates and to study risk factors for the development of disease. This report documents the findings from the NCJDSU (UK) in relation to cases of sporadic, familial, iatrogenic and vCJD diagnosed up to 31st December 1999 (with data ascertained up to 31st January 2000).

2.1 Sporadic Creutzfeldt-Jakob disease

Between 1st January 1970 and 31st December 1999, 837 cases of sporadic CJD were identified, of whom 5 cases were still alive on 31st December. Of these, 644 (77%) were classified as definite cases with the remainder classed as probable. Figure 1a shows the number of deaths each year from sporadic CJD for England and Wales between 1970 and 1999 and Figure 1b shows similar data for Scotland and Northern Ireland between 1985 and 1999. In England and Wales the number of deaths identified each year has increased from an average of about 10 per year at the beginning of the 1970s, to about 40 per year in the 1990s. A similar phenomenon has been observed in other European countries and this probably largely reflects improved case ascertainment. Over the shorter time period for which data are available for Scotland and Northern Ireland there is no clear secular trend, although the highest numbers of cases are seen in the two most recent years. Over the period 1990-1999 the average annual mortality rates from sporadic CJD per million population were 0.74 in England, 1.03 in Wales, 0.89 in Scotland and 0.44 in Northern Ireland, as shown in Table 1.

When account is taken of age and sex, the variation in recorded mortality between the different countries is not statistically significant ($p > 0.2$).

Figure 1a Deaths from sporadic CJD, England and Wales, 1970-1999





Figure 1b Deaths from sporadic CJD, Scotland and Northern Ireland, 1985-1999



Note: The horizontal lines indicate the number of deaths equivalent to crude mortality rates of 0.5 and 1 per million per year

Table 1 Deaths from definite and probable sporadic CJD by region and county of death: 01/05/1990 – 31/12/1999

	No of cases	Total no (mortality rate/million/ annum*)		No of cases	Total no (mortality rate/million/ annum*)		
ENGLAND			ENGLAND				
<u>North</u>			<u>Yorkshire & Humberside</u>				
Cleveland	1	25 (0.83)	Humberside	3	31 (0.64)		
Cumbria	8		NorthYorkshire	8			
Durham	4		South Yorkshire	9			
Northumberland	2		West Yorkshire	11			
Tyne & Wear	10		<u>East Anglia</u>				
<u>East Midlands</u>			Cambridgeshire	3	21 (1.03)		
Derbyshire	4	Norfolk	8				
Leicestershire	6	Suffolk	10				
Lincolnshire	4	<u>South West</u>					
Northamptonshire	1	22 (0.55)	Avon	8	48 (1.03)		
Nottinghamshire	7		Cornwall	4			
<u>South East</u>			Devon	10			
Bedfordshire	5		Dorset	10			
Berkshire	7		Gloucestershire	5			
Buckinghamshire	2	Somerset	4				
East Sussex	5	Wiltshire	7				
Essex	13	118 (0.68)	<u>West Midlands</u>				
Greater London	46		Hereford & Worcs.	3	32 (0.62)		
Hampshire	8		Shropshire	3			
Hertfordshire	4		Staffordshire	6			
Isle of Wight	1		Warwickshire	1			
Kent	8		West Mids (Met)	19			
Oxfordshire	6		TOTAL FOR ENGLAND				
Surrey	5		348 (0.74)				
West Sussex	8		SCOTLAND				
<u>North West</u>			Borders	1	44 (0.89)		
Cheshire	6	51 (0.82)	Central	3			
Greater Manchester	19		Dumfries & Galloway	0			
Lancashire	11		Fife	2			
Merseyside	15		Grampian	6			
WALES			Highland	1			
Clwyd	3	29 (1.03)	Lothian	12			
Dyfed	2		Strathclyde	16			
Gwent	4		Tayside	1			
Gwynedd	6		Islands (Shetland)	2			
Mid Glamorgan	6		Islands (Orkney)	0			
Powys	2		Islands (Western Isles)	0			
South Glamorgan	2		TOTAL FOR SCOTLAND				
West Glamorgan	4		44 (0.89)				
TOTAL FOR WALES							
NORTHERN IRELAND							
	7	7 (0.44)					

* Based on 1994 population by region (as published in ONS Regional Trends, 1996 edition) over the 9.67 year period of the study.

Figure 2a, 2b and 2c shows average annual age- and sex-specific mortality rates over the time periods 1970-89, 1990-94 and 1995-99, respectively. The median ages of cases at death during these time periods were 64, 66 and 65 years, respectively. In all three time periods, the mortality rates below 40 years of age were extremely low (< 0.16 /million/year). Thereafter, in all three periods, the mortality rates increased to a peak in 65-74 year olds and then declined. The height of the peak appears to have increased over time (1.96 and 3.21 cases/million/year among 65-69 year olds during 1970-89 and 1990-94, respectively, and 3.27 cases/million/year among 70-74 year olds during 1995-99). The decline in the older age groups has become less dramatic over time with the rate in those over 75 years of age declining to 2.73 cases/million/year in 1995-99, which compares with 2.13 cases/million/year in 1990-94 and 0.38 cases/million/year in 1970-89. These observed differences in the rates in the older age groups over the three time periods could be explained by an increase in case ascertainment over time or a cohort effect.

Figure 2a Age- and sex-specific mortality rates from sporadic CJD in the UK: 1970-1989
(NB: from 1970-1985 only England & Wales, thereafter UK)




Figure 2b Age- and sex-specific mortality rates
from sporadic CJD in the UK
1990-1994





Figure 2c Age- and sex-specific mortality rates
from sporadic CJD in the UK
1995-1999



An analysis of age specific trends from 1970 to 1999 (Figure 3) shows there has been an increase in mortality over time in all age groups, but that the greatest relative increase in mortality has occurred in those aged 70 years and above. Currently the mortality rate in this age group is similar to that in the age group 60-69 years. The temporal increases in mortality are statistically significant ($p < 0.001$ in the age groups 50-59, 60-69 and 70+ and $p=0.014$ in the younger age group, 40-49 years). These observations are consistent with improved case ascertainment in all ages, but with the greatest increase occurring in the elderly in recent years.

Figure 3 Trends in mortality from sporadic CJD by age: 1970- 1999




Table 2 presents, by 2-year period, the numbers of deaths underlying these trends. These data emphasise the very small numbers of cases of sporadic CJD occurring in individuals aged less than 50 years. They show clearly the substantial increase in the numbers of deaths identified among those aged 70 years and above, from around one per year in England and Wales in the early 1970s to around 20 per year in the UK in recent years.

Table 2 Cases of sporadic CJD in England and Wales (from 1970) and the UK (from 1985) by two year period

Age at death (years)	Year of death															Total ²
	70-71	72-73	74-75	76-77	78-79	80-81	82-83	84-85 ¹	86-87	88-89	90-91	92-93	94-95	96-97	98-99 ²	
10-19	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1(0)
20-29	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2 (0)
30-39	1	0	0	2	2	1	1	4	1	0	1	0	0	0	1(1)	14 (1)
40-49	2	0	2	1	1	2	1	0	3	2	2	3	4	8	7 (1)	38 (1)
50-59	7	9	11	6	11	13	12	9	5	13	18	12	14	20	24(2)	184 (2)
60-69	9	13	10	22	17	24	20	28	22	18	30	37	31	35	39(1)	355(1)
70 +	2	2	2	4	9	4	13	16	18	16	9	29	37	35	41	237 (0)
Total	21	24	25	35	40	45	47	57	49	50³	60	81	86	99	113 (5)	832³ (5)


¹ Up to 1984, cases from England and Wales only. From 1985 onwards, cases from Scotland and Northern Ireland are included

² Deaths up to 31st December 1999. Numbers in parentheses indicate additional cases alive on 31st December 1999.

³ Total includes one case whose age at death was unknown

Standardised mortality ratios (SMRs) for the 11 standard regions of the UK for the period 1st May 1990 to 31st December 1999 were calculated. Figure 4 shows the 10 regions of Great Britain. Northern Ireland has an SMR of 87. After adjusting for the age/sex distribution of the population, the variation in mortality rates between the different regions is not statistically significant ($p > 0.2$). Regions of relatively high mortality are East Anglia (SMR=129), the South West (SMR=126) and Wales (SMR=126). Low mortality rates were observed in East Midlands (SMR=72), the West Midlands (SMR=82) and Yorkshire & Humberside (SMR=83). The SMRs for the other five regions all lay between 87 and 117. The highest SMR (129 in East Anglia) arose from 21 cases observed compared with 16 expected, an excess of about 1 case every 2 years. In the South West and Wales the excess numbers of cases were approximately 10 and 6 respectively.

Figure 4 **Standardised mortality ratios (SMRs) by standard region, Great Britain, May 1990 - December 1999**



2.2 Genetics and sporadic CJD

The distribution of codon 129 genotypes in sporadic CJD has been analysed since the inception of the Unit in 1990. The overall distribution of codon 129 genotypes (73% MM, 12% MV, 15% VV) is consistent with findings from other European countries. There is no evidence of a significant change in the codon 129 distribution in sporadic CJD between the periods 1990-1995 and 1996-1999.

Table 3

Deaths from sporadic CJD	MM (%)	MV (%)	VV (%)
Deaths from 1 May 1990 - 31 December 1995	95 (75)	14 (11)	17 (13)
Deaths from 1 Jan 1996 - 31 December 1999	82 (70)	15 (13)	20 (17)
Total	177 (73)	29 (12)	37 (15)
Normal caucasian population pooling data from five studies⁴	(39)	(50)	(11)

2.3 Variant Creutzfeldt-Jakob disease

Up to 31st December 1999, 51 cases of vCJD had been identified in the UK (49 definite, 2 probable), and a further case was confirmed in January 2000. Twenty-eight (54%) of the 52 cases were women. The median age at onset of disease was 28 years and the median age at death 29 years (compared with 65 years for the median age at death for sporadic CJD). The two youngest cases were aged 14 years at onset while the oldest case was aged 53 years. All cases for whom genetic data are available (49) were methionine homozygotes at codon 129 of the PrP gene. The median duration of illness was 14 months (range 7-38). The median delay between onset of disease and confirmation of the diagnosis of vCJD was 15 months (with a range 7.2 - 32.0 months). This has not decreased over time.

⁴ Alperovitch A, Zerr I, Pocchiarri M, et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. *Lancet* 1999; 353: 1673-1674.

The number of deaths (11) in the last quarter of 1998 was higher than previous quarters. In 1999 the number of deaths reverted to about 3 per quarter, similar to numbers observed in quarters prior to the last quarter of 1998 (Figure 5). Analyses which adjust for delays in reporting and confirmation have found no evidence that the incidence rate of vCJD has increased significantly during the period 1994-1999 (N. Andrews, personal communication).

Figure 5 Cases of vCJD by date of onset





Figure 6 and Table 4 show the geographical distribution, by place of residence at onset, of the 52 cases of vCJD with onset in the UK. This shows that the cases to date have been widely spread geographically.

Figure 6

Geographical distribution of places of residence
at onset of symptoms of 52 vCJD cases



**Table 4 Deaths from definite and probable vCJD
by region and county of onset: 1 May 1995 - 31 January 2000**

	No of cases	Total no (mortality rate/million/ annum*)		No of cases	Total no (mortality rate/million/ annum*)	
ENGLAND			ENGLAND			
<u>North</u>			<u>Yorkshire & Humberside</u>			
Cleveland	1	5 (0.34)	Humberside	2	7 (0.29)	
Cumbria	1		North Yorkshire	1		
Durham	0		South Yorkshire	1		
Northumberland	0		West Yorkshire	3		
Tyne & Wear	3		<u>East Anglia</u>			
<u>East Midlands</u>			Cambridgeshire	1	1 (0.10)	
Derbyshire	0	Norfolk	0			
Leicestershire	2	Suffolk	0			
Lincolnshire	0	2 (0.10)	<u>South West</u>			
Northamptonshire	0		Avon	0	2 (0.09)	
Nottinghamshire	0		Cornwall	0		
<u>South East</u>			Devon	1		
Bedfordshire	0		Dorset	0		
Berkshire	0	Gloucestershire	0			
Buckinghamshire	0	Somerset	0			
East Sussex	0	Wiltshire	1			
Essex	0	<u>West Midlands</u>				
Greater London	4	14 (0.16)	Hereford & Worcs.	0	1 (0.04)	
Hampshire	4		Shropshire	0		
Hertfordshire	1		Staffordshire	0		
Isle of Wight	0		Warwickshire	1		
Kent	3		West Mids (Met)	0		
Oxfordshire	1		TOTAL FOR ENGLAND			
Surrey	1		38 (0.16)			
West Sussex	0	WALES				
<u>North West</u>			Clwyd	1	4 (0.29)	
Cheshire	2	6 (0.20)	Dyfed	1		
Greater Manchester	2		Gwent	0		
Lancashire	0		Gwynedd	1		
Merseyside	2		Mid Glamorgan	0		
			Powys	0	0	
			South Glamorgan	0		
			West Glamorgan	1		
			SCOTLAND			
TOTAL FOR WALES			Borders	0	9 (0.37)	
NORTHERN IRELAND		1 (0.13)	Central	0		
			Dumfries & Galloway	0		
			Fife	1		
			Grampian	0		
			Highland	0		
			Lothian	4		
			Strathclyde	3		
			Tayside	0		
			Islands (Shetland)	0		
			Islands (Orkney)	1		
			Islands (Western Isles)	0		
			TOTAL FOR SCOTLAND			

* Based on 1994 population by region (ONS Regional Trends, 1996 edition) over the 4.75 year period

The crude cumulative mortality rates for 1995-1999 based on 51 vCJD cases (excluding one case from Northern Ireland) and the population aged 16-54 years by region of residence in 1991 are shown in Table 5. The variation in mortality rates between the different regions is not statistically significant ($p>0.3$). Adjusting for age and sex distribution of the regions does not alter this finding ($p>0.3$). Regions of relatively high mortality are the Northern Region and Scotland, with cumulative rates of 3.14 and 2.98 per million of the population over the 5-year period. West Midlands and East Anglia have relatively low cumulative mortality rates of 0.36 and 0.93 per million of the population, respectively. Inspection of Table 5 reveals that the 4 most northern regions (Northern, North West, Yorkshire and Humberside and Scotland) contain the three highest rates and the fifth highest rate. The crude cumulative mortality rates for the "North" versus the "South" are shown in Table 6 and are statistically significantly different ($p = 0.02$). As before, this finding remains after adjusting for age and sex ($p=0.02$). However, these results must be interpreted with caution since this comparison was performed following examination of the data and was not based on a prior hypothesis. No such geographical association was found for sporadic CJD. Further analyses are being carried out and will be reported.

Table 5 Distribution of 51 vCJD cases by region of residence in 1991.

Standard region	Population aged 16-54 at the 1991 census (%)	Number (rate/million ⁵) of vCJD cases
East Anglia	1,072,018 (4)	1 (0.93)
East Midlands	2,121,678 (7)	4 (1.89)
West Midlands	2,749,699 (9)	1 (0.36)
Northern	1,592,257 (5)	5 (3.14)
North-West	3,293,814 (11)	6 (1.82)
South-East	9,469,745 (32)	14 (1.48)
South-West	2,379,370 (8)	3 (1.26)
Yorkshire & Humberside	2,567,630 (9)	7 (2.73)
Scotland	2,684,004 (9)	8 (2.98)
Wales	1,461,006 (5)	2 (1.37)
Total	29,393,174 (100)	51 (1.74)

⁵ over the five years 1995-1999

Table 6 Comparison of vCJD rates in 4 northernmost regions with those further south according to place of residence in 1991

Standard region	Population (millions) aged 16-54 at the 1991 census (%)	Number (rate/million) of vCJD cases
"North" (North West, Yorkshire & Humberside, Northern, Scotland)	10.1 (34)	26 (2.57)
"South" (South West, South East, Wales, West Midlands, East Midlands, East Anglia)	19.3 (66)	25 (1.30)
Total	29.4 (100)	51 (1.73)

2.4 An analysis of clustering of vCJD

An analysis to look for possible clustering of the places of residence in 1991 of 48 vCJD was performed (48 being the number of confirmed cases at the time of analysis). The year 1991 was chosen as it lies somewhere between when peak exposure to BSE agent is expected to have been if the SBO ban was effective in preventing human exposure to the BSE agent (1989) and when peak exposure is expected to have been if SBO ban was largely ineffective (1992/1993). Also, accurate small area census data by age are available for 1991.

The places of residence in 1991 of 48 vCJD cases were identified and the grid references for their census enumeration districts recorded. All possible pairs of cases were then examined to determine how close together the cases were living in 1991. The numbers of pairs of cases living within 1, 5, 10 or 20 km of each other were recorded.

To determine the expected distributions of the numbers of pairs of people in the UK population living within these distances of each other, enumeration district level data from the 1991 census was used. The age distribution of the 48 vCJD cases in 1991 was used to draw repeated age-weighted samples of 48 individuals from the census data. For each of

these repeated samples the numbers of pairs of individuals living within 1, 5, 10 or 20km of each other were computed. One thousand independent samples were drawn.

The results show that no pairs of cases were observed living at a distance of less than 1km (Table 7). There were 5 pairs of cases living within 5 km of each other, 9 within 10 km of each other and 24 within 20 km of each other. These observed numbers of pairs of cases do not represent an excess over the numbers that might be expected by chance, in the absence of any geographical clustering. This analysis provides no evidence for local clustering of vCJD cases.

Table 7 Numbers of pairs of cases living within 1 km, 5 km, 10 km and 20 km of each other in 1991.

	Number of pairs at a distance of			
	< 1 km	< 5 km	< 10 km	< 20 km
Pairs of cases (observed)	0	5	9	24
Median of 1000 random samples	0	4	9	27
95 th percentile of 1000 random samples	1	7	18	48
99 th percentile of 1000 random samples	2	10	22.5	63

2.5 Iatrogenic Creutzfeldt-Jakob disease

Since 1970, up to 31st December 1999, 40 cases of CJD attributable to iatrogenic exposure have been identified, 6 in individuals receiving dura mater implants and 34 in individuals who had received human-derived growth hormone (hGH) or gonadotrophin. The mean age at death of the latter group was 29½ years (with a range of 20-45 years) and for the dura mater cases was 43 years (range 27-59 years).

The first identified iatrogenic case was a dura mater recipient who died in 1979. The first hGH-related death occurred in 1985. Between 1st May 1990 and 31st December 1999 there were 29 CJD deaths in hGH recipients, an average of nearly 3 deaths per year.

2.6 Familial Creutzfeldt-Jakob disease

Thirty-five cases of familial CJD have been identified since 1970, excluding cases of GSS. Of these, 33 were resident in England and 2 were resident in Wales. Thirteen of the cases had insertions in the coding region of the PrP gene, 9 carried the mutation at codon 200 (Glu-Lys), 2 at codon 178 (Asp-Asn, both with methionine at codon 129), 1 at codon 117 (Ala-Val) and 1 at codon 210 (Val-Ile). Nine were identified as familial on the basis of relatives known to have had CJD (one with a relative known to have an insertion, one with a relative known to have the codon 200 mutation). The mean age at death was 55.6 years (with a range 38 - 68 years).

2.7 Transfusion Medicine Epidemiology Review

A collaborative study between the CJDSU and the UK Blood Transfusion Services has been in progress since 1997 to examine the possibility of transmission of CJD via blood transfusion. Patients with sporadic CJD and matched controls, who were reported to have donated blood, were identified and a single look-back exercise was performed. The details of the recipients who received components from these donors are held on the CJDSU database in order to check whether any subsequently develop CJD. This process was extended to vCJD cases. So far, 30 recipients have been identified in the CJD study and 12 in the vCJD study. None has appeared as suspect cases on the CJDSU register.

The reverse process is also underway. The study group is sporadic CJD patients and matched controls who have received blood. The relevant donors are traced and then linked to the CJDSU register. To date, 282 donors have been identified and none appear on the register. This study was also extended to vCJD. Only one vCJD patient was known to have received blood; 103 blood components were involved. None of the donors appear on the register.

(Collaborators on this project: Dr P.E. Hewitt and Dr C.A. Llewelyn).

2.8 Study of Progressive Intellectual & Neurological Deterioration (PIND)

The aim of this project is to use the mechanism of the British Paediatric Surveillance Unit to identify all cases of progressive intellectual and neurological deterioration in children in the UK, particularly those with features suggestive of vCJD. All cases are discussed by an expert neurological advisory group of seven paediatric neurologists which allocates the cases to a diagnostic category.

After 29 months of surveillance, 773 children have been reported. 570 cases have been discussed by the expert group. Of these, 322 have been classified as progressive intellectual and neurological deterioration with a recognised cause. 150 have yet to be allocated to a diagnostic group (pending further investigations and follow-up). 24 have been classified as idiopathic progressive intellectual and neurological deterioration (non-CJD). 220 have been classified as 'no case'. 56 cases are in the process of being followed up. So far one case of definite vCJD and 2 suspected cases have been identified.

(Collaborators: Dr C. Verity, Dr A. Nicoll, Ms G. Devereux).

2.9 Extent of misclassification of death from CJD Study

The NCJDSU collaborated with the Office of National Statistics and the London School of Hygiene and Tropical Medicine in this study. 1485 deaths from selected neurological disorders were identified in people aged 15-44 years in England during 1979-1996. All traceable clinical records (705,48%) were then reviewed to determine whether any cases of sporadic CJD or vCJD may have been misclassified as another illness. No new cases were detected in this sample of deaths which were considered most likely to have included any misclassified deaths. This provides some support for the completeness of CJD surveillance in England during this period.⁶

(Collaborators: Dr A. Majeed, Professor M. Coleman)

⁶ Majeed A, Lehmann P, Kirby L, Knight R, Coleman M. Extent of misclassification of death from Creutzfeldt-Jakob disease in England 1979-96: retrospective examination of clinical records. *BMJ* 2000; 320: 145-7.

SECTION**3**

3. Case-Control Study

Methods

A case-control study of CJD has been carried out in the UK since May 1990 to investigate potential risk factors for the disease. Relatives of patients with suspect CJD have been interviewed using a standard questionnaire which includes a wide range of questions relating to putative risk factors for CJD including occupational, dietary and medical history. Up until 1997, for each suspect case, a patient at the same hospital was identified as a control. At the end of 1997 the design of the study was changed. Instead of hospital controls, it was decided to recruit community controls, matched for sex and age ± 4 years, through general medical practices (4 for each case of vCJD and one for each case of sporadic CJD). When possible, a relative of the same degree as for the case was interviewed using the standard questionnaire. If this was not possible the control was interviewed directly using the standard questionnaire. These community controls would be more suitable for the investigation of potential medical risk factors. Ethical clearance for the revised study design was received from the Multi-Centre Research Ethics Committee for Scotland in October 1998. In addition to the community controls, the revised protocol specifies that a further control group will consist of individuals referred to the CJDSU as suspect cases of CJD who are subsequently shown to have some condition other than CJD. This control group has been used in the analyses presented in this report.

Since the end of 1998, Local Research Ethics Committee (LREC) approval has been sought for each general practice in the study. Following each LREC approval, the complex and time consuming process of control recruitment commenced. By the end of 1999, 5 control risk factor questionnaires had been completed (relating to 2 vCJD cases).

Variant CJD

Because few community controls have been recruited to date, the analyses are based on data from 51 cases of vCJD and 27 controls - individuals who were referred to the CJDSU as

suspect vCJD and who either subsequently recovered (9), or who developed another pathological diagnosis (11) or who are thought very unlikely to be cases of vCJD (that is, recovery or an alternative diagnoses is expected) (7). These controls are not age- or sex-matched to the cases and their basic demographic characteristics are shown in Table 8. The median age of the controls is slightly older than the cases, 32 years compared with 28 years, but this does not reach statistical significance ($p=0.092$).

Table 8 Demographic characteristics of cases of vCJD (n= 51) compared to controls (n= 27)

	Gender		Median age at onset (years)	Range of age at onset (years)
	Males (%)	Females (%)		
Cases	24 (47)	27 (53)	28	14- 53
Controls	12 (44)	15 (56)	32	11- 58

3.1 Medical risk factors for vCJD

Thirty-one of the cases were reported to have had some sort of operation/surgical procedure (other than dental procedures) prior to the onset of their illness compared with 19 controls (Table 9). There is no evidence to suggest that cases were more likely than controls to have had operations in the past.

Table 9 Reported operations/surgical procedures from 51 cases of variant Creutzfeldt-Jakob disease and 27 controls.

	% of cases (n = 51)	% of controls (n= 27)
Any operation	61 <small>n=31</small>	70
Abdominal operation [†]	22	26
Neurological operation	0	0
Orthopaedic operation	10	7
Eye operation	2	7
Tonsillectomy	8	19
Appendicectomy	4	19

[†]Includes appendicectomy

Table 9 also shows that when specific operations/surgical procedures are examined, cases do not appear to have had more operations compared with controls.

Five of the 51 cases were reported by relatives to have had a history of blood transfusion compared with 2 of the 27 controls. It is of note in relation to the TMER study that a record of blood transfusion was not traced in 4 cases.

3.2 Dietary risk factors for vCJD

The reported consumption of various different meats and meat products by cases and controls in the period since 1980 (except for 5 cases and 4 controls where the period is from 1985 due to a change in the questionnaire) is shown in Table 10.

Table 10 Reported consumption of different types of meat from 51 cases¹ of variant Creutzfeldt-Jakob disease and 27 controls².

	% of cases (n=51)	% of controls (n=27)
Beef	98	96
Sausages	88	93
Burgers	88	88
Meat pies	86	87
Venison	25	22
Veal	18	35
Brain	0	4

¹ In 5 cases the dietary history was recorded from 1985 onwards. In the remainder, it was taken from 1980.

² In 4 controls the dietary history was recorded from 1985 onwards. In the remainder it was taken from 1980.

Almost all cases and controls were reported to have eaten beef, sausages, burgers and meat pies. Thirteen cases and 6 controls were reported to have eaten venison ($p>0.7$), while 9 cases and 9 controls were reported to have eaten veal ($p=0.096$). Only one control was reported to have eaten brain. Looking at frequency of consumption of beef, cases were reported to have eaten beef more frequently than controls (Table 11), however this was not statistically significant ($p>0.2$). A similar analysis carried out for last year's report (1998) using hospital controls showed that cases were reported to have consumed beef more frequently than

controls ($p=0.02$). It was suggested that this finding may have been due to recall bias. This conclusion is supported by the analysis carried out in this year's report.

However, while these latter findings are consistent with there being no association, we cannot exclude the possibility that such associations exist.

Table 11 Frequency of consumption of beef by 51 cases of vCJD and 27 controls

Frequency of consumption	% of cases (n= 51)	% of controls (n= 27)
< 1/ month	16	22 ¹
once a month or more	30	41
more than once per week	54	37

¹includes one control who never ate beef

We also analysed the frequency of consumption of three food items, which may have contained mechanically recovered meat (MRM) (burgers, meat pies and sausages). When a person had different consumption rates of each of these food items reported, they were categorised according to the highest frequency of any of the food items. As can be seen in Table 12, there is widespread consumption of these food items in both cases and controls, with no significant difference between them ($p>0.2$).

Table 12 Frequency of consumption of burgers, meat pies and sausages by 51 cases of vCJD and 27 controls

Frequency of consumption	% of cases (n= 51)	% of controls (n= 27)
< 1/ month	10	19 ¹
once a month or more	39	41
more than once per week	51	41

¹includes one case and one control who never ate burgers, meat pies or sausages

Three cases (6%) and three (15%) controls reported that they had been vegetarians for a period of at least one year ($p > 0.4$).

3.3 Occupation and variant CJD

Table 13 presents a list of specific occupations for cases and controls, which were examined as potential at risk occupations for vCJD. Fourteen cases reported working in the catering industry compared with 5 controls, which was not statistically significant ($p>0.4$). Four cases worked in the meat industry and 3 in the medical/ medical related profession compared with 2 and 3 controls, respectively.

Table 13 Reported life- time occupations from 51 cases of variant Creutzfeldt-Jakob disease and 27 controls.

	% of cases (n=51)	% of controls (n=27)
Medical/ paramedical/ nursing/ dentistry	6	11
Animal laboratories	0	0
Pharmaceutical laboratories	0	0
Other research laboratories	0	4
Animal farming/ veterinary medicine	6	4
Meat industry (butcher's/ abattoirs/ rendering plants, etc.)	8	7
Catering industry	27	19
Other occupations involving animal products	2	0

3.4 Conclusion

We have found no evidence of any dietary, iatrogenic or occupational risk for vCJD.

SECTION**4*****Neuropathology***

4.1 Statement of Progress

The neuropathology laboratory in the CJD Surveillance Unit continues to maintain an increasing workload in terms of both diagnostic and research activities. In particular, the activities of the protein laboratory have greatly expanded, to allow a more precise characterisation of all CJD cases. The neuropathology laboratory maintains close liaison with other neuropathology laboratories across the UK, which has been reinforced by the activities of the National Retrospective Review of CJD and Related Disorders. This helps facilitate autopsy arrangements across the UK, the collection and transport of diagnostic materials and the brain and tissue banking activities. The high post-mortem referral rates for suspected CJD cases have been maintained in 1999. We are most grateful to all the neuropathologists, general pathologists and their technical, secretarial and autopsy room staff for their continuing support of the National CJD Surveillance Project.

4.2 Surveillance and Workload during 1999

A detailed breakdown of laboratory activities is summarised in Tables 14 and 15. These demonstrate that the case workload in relation to the previous reported period (20 months) has been increased, with core diagnostic activities related to the identification of CJD cases in the UK. A number of cases of prospective CJD have been referred from Europe and other countries in the world, including one case that was subsequently confirmed as vCJD. As before, the commonest alternative diagnosis to CJD was Alzheimer's disease and dementia with Lewy bodies, which are diagnosed according to standardised international criteria. In addition to these, smaller numbers of rarer conditions were identified (see Table 14). In addition to these tabulated cases, diagnostic material in the form of stained slides is submitted

to the Unit for review; these cases do not appear in this file since no additional technical work is required in the Surveillance Unit laboratory.

Table 14 Breakdown of Laboratory Activities:
Period 1st January 1999 – 31st December 1999

	CURRENT YEAR	PREVIOUS YEAR (20 months)	
REFERRED CASES (UK)			
No evidence of CJD*	28	46	
Iatrogenic CJD (GHT)	5	7	
Gerstmann-Straussler-Scheinker	0	3	
Fatal Familial Insomnia	0	0	
Sporadic CJD*	46	64	
vCJD*	14	17	
Other †	11	19	
Alzheimer's disease	10	15	
Dementia with Lewy Bodies	4	8	
Research Project (ocular material)	3	0	
REFERRED CASES (EU)	12	17	
REFERRED CASES (ROW)	2	22	
<u>TOTAL NUMBER OF CASES</u>	135	218	
NOTES			
* In some cases, more than one specimen has been referred to the Unit and these cases have therefore been allocated multiple laboratory numbers.			
† Other:			
Multiple Sclerosis	1	Hepatic Encephalopathy	1
Mitochondrial Encephalomyelopathy	1	Demyelination	1
Hypoxia	1	B-Cell Lymphoma	1
Metastatic carcinoma	1	Multifocal Ischaemic Damage	1
Viral Encephalitis	1	Oedema & Mild Gliosis	1
Multifocal Calcifying Leucoencephalopathy	1		
Abbreviations:			
GHT: Growth Hormone Therapy			
EU: European Union			
ROW: Rest of world			

Table 15 Monthly breakdown of the number of paraffin blocks cut and stained in the CJD laboratory for diagnostic and research purposes (including CNS and other human tissues and non-human research specimens)

January 1999 - December 1999

	Blocks	Slides
January 1999	539	2165
February 1999	611	2331
March 1999	117	544
April 1999	172	743
May 1999	38	153
June 1999	296	1059
July 1999	368	1308
August 1999	435	1452
September 1999	161	642
October 1999	122	509
November 1999	197	720
December 1999	161	505
TOTAL	3217	12131

Monthly Average Block Total: 268
Monthly Average Slide Total: 1011

4.3 Protein Laboratory

The protein laboratory in the NCJDSU was established in June 1998 with the recruitment of Dr Mark Head from Columbia University (NYC). Since no previous report has been made to the Department, this report covers the period from the establishment of the lab until the present time.

4.3.1 Aims

1. Introduction of Western blot analysis into the NCJDSU repertoire of differential diagnostic tests for CJD and its subtypes, with particular reference to vCJD.
2. Research into pathogenesis and phenotypic variation of CJD.
3. Participation in the development of novel diagnostic tests for vCJD.

4.3.2 Western Blot Analysis

Background and Nomenclature

The classification of proteinase K resistant prion protein (PrP^{res}) isotypes found in the brains of patients suffering from CJD has proved controversial with the debate centering on the possible number and molecular size of the non-glycosylated PrP^{res} protease resistant PrP protein. This is an important issue since PrP isotypes may equate to “strains” of the infectious agent accounting for phenotypic variation within and between forms of CJD. Our results dictate that we adopt the nomenclature of Type 1 (21kDa) and Type 2 (19kDa) PrP^{res} isotypes. Further classification is possible on the basis of the proportion of the three glycoforms (di-, mono-, and non-glycosylated PrP) present. The defining characteristic of PrP^{res} from cases of vCJD, namely the predominance of diglycosylated PrP^{res} is referred to by us as Type 2B. Our experience with PrP^{res} isotyping and the place that it occupies in the diagnosis of vCJD is described in a forthcoming publication.

CNS Tissues

Analysis of all suspected CJD cases referred to the unit (where frozen tissue is available) is now routinely carried out and the results available within the same time frame as those from histological tests. Post-mortem brain tissue, usually frontal cortex, has been analysed from 155 cases of suspected or confirmed CJD and neurological controls. This includes both a retrospective survey of cases held in the NCJDSU brain bank and cases analysed on receipt of frozen brain tissue by the NCJDSU following autopsy, as part of the ongoing surveillance program in the UK. The breakdown of cases is considered according to final diagnosis as follows (Table 16):

Table 16

<i>Diagnosis</i>	<i>Type</i>	<i>PrP^{res} +ve CNS</i>	
CJD	Sporadic	100/100	
	Variant	38/38	
	Iatrogenic	Growth hormone	3/3
		Dura mater graft	2/2
	Familial	GSS	1/2
		FFI	0/1
Other	Alzheimer disease	0/4	
	Lewy body dementia	0/2	
	Other	0/3	

PrP^{res} positivity on Western blot analysis accurately distinguishes between CJD whether sporadic, variant or iatrogenic (143/143) and neurological diseases with an alternative final diagnosis (0/9). PrP^{res} in familial forms of CJD was less consistently observed (1/3), however the aetiology of these forms of disease are demonstrable by *PRNP* sequencing.

Since sporadic CJD is the major differential diagnosis for vCJD and these two classes represent the majority of cases examined, they are considered further. The PrP^{res} isotype determined by Western blotting is shown in conjunction with the *PRNP* codon 129 status, which is known to modify disease susceptibility and phenotype. Of the 138 PrP positive sporadic CJD and vCJD cases, unequivocal isotype classification could be made in 134 cases. Of these the codon 129 status is known in 123 cases and their distribution is shown below (Table 17):

Table 17

<u>Diagnosis</u>	<u>129</u>	<u>Type 1</u>	<u>Type 2A</u>	<u>Type 2B</u>	<u>Total</u>
sporadic CJD	M/M	51	8	0	59
	M/V	4	10	0	14
	V/V	3	12	0	15
		58	30	0	88
<u>Total</u>					
vCJD	M/M	0	0	35*	35*
	M/V	0	0	0	0
	V/V	0	0	0	0
<u>Total</u>		0	0	35	35

* includes one case outwith the UK

These results show isotypic/genotypic diversity in sporadic CJD, however this variation appears non-random. For example 58% of all sporadic CJD cases are methionine homozygotes with type 1 PrP^{res} and only 3% are type 1 valine homozygotes. The contention that these isotype/genotype groups represent distinct clinico-pathological entities of sporadic CJD will be the subject of future studies. Part of this data has been included in an in depth histological study of sporadic CJD in valine homozygotes which has been submitted for publication.

In contrast to sporadic CJD, vCJD is stereotyped, with all cases thus far examined being methionine homozygotes and having a 2B PrP^{res} isotype. Densitometric analysis of glycoform ratios is ongoing. However analysis of eight MM2 cases of sporadic CJD with an equal number vCJD cases (also MM2) show the glycoform ratio groups to be non-overlapping, confirming the usefulness of the type 2B pattern in the diagnosis of vCJD. The failure to find this glycoform signature in CJD diagnosed as sporadic in young M/V or V/V individuals suggests that these cases do not represent vCJD in these genotypes. A glycoform ratio more closely resembling vCJD is however found in GSS.

The biochemical basis of the type 1 and type 2 isoforms has been addressed by contributing sporadic CJD and vCJD brain tissue isotyped in the protein lab to an N-terminal sequencing study conducted in another centre.

Five cases of CJD that contained detectable PrP^{res} were seen that could not be accommodated in the above classification system. Two MM sporadic CJD, one VV sporadic CJD and a case of GSS displayed a non-glycosylated PrP^{res} mobility reproducibly intermediate between Type 1 and Type 2. Our own studies show that a similar mobility type results from metal ion chelation prior to proteinase K treatment of Type 1 extracts. We are currently investigating the possibility that these intermediate types represent endogenously or artifactually metal-depleted PrP.

The remaining unclassifiable case was a young VV individual with atypical clinical features, referred to the NCJDSU from outside the UK. Isotyping of a cortical biopsy showed Type 1 PrP^{res}, however after a protracted illness, analysis of autopsy cortical material showed Type 2 PrP^{res} and a glycosylation ratio markedly different from the biopsy material and more closely resembling that of GSS. This finding and recently published data showing isotype diversity

in a subset of sporadic CJD cases has prompted us to undertake a neuroanatomical survey of isotypes in sporadic CJD and vCJD. Preliminary results confirm isotype diversity within and between cases of sporadic CJD but indicate a homogeneous isotype in vCJD.

Peripheral Tissues

The possible presence of CJD infectivity in peripheral tissues of individuals with preclinical CJD presents a risk to public health. It is therefore important to determine the tissue distribution of PrP^{res} as a surrogate marker for infectivity in peripheral tissues. The challenge involved in such studies is that PrP^{res} levels are lower than in the CNS. The Protein Lab is currently involved in the parallel development of three approaches to address this question, namely Dissociation Enhanced Lanthanide Fluoro Immuno Assay (DELFIA), Capillary Electrophoresis and modifications of the standard Western blot procedure. Initial studies of peripheral tissues by Western blotting proved inconclusive however centrifugal concentration of PrP^{res} has allowed us to increase the sensitivity of our Western blotting procedure by up to a factor of 100. Using this technique we have analysed post-mortem tonsil with the following results:

Table 18

Diagnosis	Number of Cases	PrP^{res} positive
Lewy body dementia	1	0/1
sporadic CJD	4	0/4
iatrogenic CJD (growth hormone)	1	0/1
vCJD	4	4/4

These studies confirm the specificity of tonsillar PrP^{res} to vCJD and show tonsillar PrP^{res} to be more extensively glycosylated than PrP^{res} from the brain of the same individual. The negative result from the growth hormone therapy iatrogenic CJD tonsil is of interest since it demonstrates that peripheral infection with the CJD agent may be insufficient in itself to result in a PrP^{res} positive tonsil. We plan to extend this work to: i) further cases of CJD, ii) other forms of CJD, iii) other lymphoreticular organs, iv) the peripheral nervous system, and v) organs commonly used for transplantation.

4.3.3 Other activities

- i. Collaboration with Dr Andrei Schmakov (University of Edinburgh) on the expression of PrP^C in the human enteric nervous system.
- ii. Analysis of PrP^C expression in the context of neurological disorders other than CJD (in collaboration with Prof. Jeanne Bell and Dr Neil McLennan, University of Edinburgh).
- iii. Pilot study to assess the feasibility of using *Xenopus* oocytes as a model system in which to study the conversion of PrP^C to PrP^{Sc} (in collaboration with Dr John Connolly, Strathclyde University).

4.4 Brain banking activities

The bank of fixed and frozen tissues in the surveillance unit was used extensively in 1999 for research purposes within the unit and with collaborators in the UK and overseas (see Table 19). No problems were encountered with Year 2000 compatibility in the Tissue Bank, and this facility is now being reorganised to allow the most efficient storage of frozen brain and organ samples, blood, DNA and CSF samples.

4.5 Health and Safety

The laboratory was inspected by a representative of the National Health and Safety Executive. No major problems were identified in the laboratory as a result of this inspection. The laboratory continues to receive numerous requests for advice and guidance on the safe handling of CJD tissues, autopsy procedures, burial and cremation. Careful attention to Health and Safety protocols within the unit has resulted in no accidents occurring this year in the laboratory and no problems with the handling and transport of materials to and from the laboratory.

Table 19 National and International Requests for Fixed and Frozen Material from the CJD Surveillance Unit's Brain and Tissue Bank

January 1999 - December 1999

Recipient	No. of Cases	Recipient	No. of Cases
Professor C Abee, Alabama, USA	3	Dr P Minor, Hertfordshire, UK	4
Dr J Anderson, Cambridge, UK	3	Dr M Mirakhur, Belfast, N. Ire.	5
Dr N Bogdanovic, Sweden	4	Dr D Moffat, Eastbourne, UK	1
Dr L Bridges, Leeds, UK	4	Dr Morgan, Scarborough, UK	1
Dr J Broome, Liverpool, UK	2	Dr T Moss, Bristol, UK	2
Dr P Brown, Maryland, USA	3	Dr I Nauroz, Kirkcaldy, UK	1
Dr M Bruce, Edinburgh, UK	7	Dr J Neal, Cardiff, UK	6
Dr M Carey, Birmingham, UK	12	Dr C O'Brien, Swansea, UK	1
Dr J Cesbron, Lille, France	1	Dr R Perry, Newcastle, UK	1
Professor J Collinge, London UK	3	Dr J Polo, Santander, Spain	2
Dr D Crooks, Hull, UK	3	Professor S Prusiner, San Francisco, USA	12
Dr S Dealler, Leeds, UK	2	Dr Raafat, Birmingham, UK	1
Dr D Ellison, Southampton, UK	3	Dr H Reid, Manchester, UK	5
Dr M Esiri, Oxford, UK	1	Dr T Révész, London, UK	4
Dr M Farrell, Dublin, Ireland	1	Dr K Robson, Nottingham, UK	1
Dr J Fraser, Edinburgh, UK	12	Dr E Ruban, Leicester, UK	1
Dr P Gambetti, Ohio, USA	3	Professor A Sau, Marmara, Turkey	2
Dr J Geddes, London, UK	6	Dr Scoones, Middlesbrough, UK	2
Professor F Gray, Cedex, France	1	Dr S Shanker, Bangalore, India	1
Dr J Hope, Compton, UK	15	Dr R Somerville, Edinburgh, UK	2
Dr P Ince, Newcastle, UK	2	Dr M Stewart, Lancaster, UK	1
Dr G Jansen, Utrecht, Holland	5	Dr A Taratuto, Buenos Aires, Argentina	2
Dr C Jarius, Vienna, Austria	1	Dr W Timperley, Sheffield, UK	4
Dr R Kisilevsky, Ontario, Canada	1	Professor R Weller, Southampton, UK	3
Dr Kitamoto, Sendai, Japan	3	Dr S Wells, Bolton, UK	1
Dr S Lehmann, Montpellier, France	3	Dr S Wharton, Edinburgh, UK	1
Dr P Liberski, Lodz, Poland	2	Ms. L Wheatley, Leicester, UK	1
Professor J Lowe, Nottingham, UK	8	Dr H Whitwell, New Zealand	1
Dr J Mac Kenzie, Aberdeen, UK	2	Dr P Wilkins, London, UK	1
Dr D Mann, Manchester, UK	2	Dr Wright, Dunedin, New Zealand	1
Dr J Manson, Edinburgh, UK	1	Dr J Wyatt, Leeds, UK	6
Dr A Marshall, Essex, UK	2	Dr K Zarkovic, Zagreb, Croatia	5

4.6 Research Projects

The laboratory is involved in several major research projects in relation to vCJD, including a Retrospective Study of PrP in Tonsil and Appendix Tissues, and the National Retrospective Review of CJD and Related Disorders. The laboratory also contributes to the EC BIOMED2

neuropathology project headed by Professor Budka in Vienna and the BIOMED2 project for the Surveillance of CJD in the European Community (led by Professor Will). Quantitative studies in the neuropathology laboratory are incorporated into an EU-funded study (QAMRIC) which involves correlation and quantitation of all aspects of neuropathology and neuro-imaging in CJD. The unit is also involved in two parallel collaborative projects to develop biochemical techniques capable of detecting the abnormal isoform of PrP in human peripheral tissues, including blood. The first technique is Dissociation Enhanced Lanthanide Fluoro Immuno Assay (DELFIA) in collaboration with, Dr James Hope (IAH, Compton) and Dr Marc Turner (SNBTS, Edinburgh). The second is to employ Capillary Electrophoresis with Laser-Induced Fluorescence (CE-LIF) in collaboration with Dr Mary Jo Schmerr (National Animal Disease Center, Ames, IA, USA).

SECTION
5

Publications

1989

1. Scott PR, Aldridge BM, Clarke M, Will RG. Bovine spongiform encephalopathy in a cow in the United Kingdom. JAVMA 1989;195: 1745-1747.

1990

2. Will RG. Prion Disease. Lancet 1990; 336: pp369.
3. Will RG. Is there a potential risk of transmission of BSE to the human population and how may this be assessed? In: Subacute Spongiform Encephalopathies - Proceedings of a Seminar in the CEC Agricultural Research Programme held in Brussels, 12-14 November 1990. Eds: R. Bradley, M. Savey & B. Marchant. Published by Kluwer Academic Publishers 1991.

1991

4. Bell JE and Ironside JW. Department of Health National Surveillance of Creutzfeldt-Jakob Disease. Bulletin of the Royal College of Pathologists, April 1991, pp 9-10.
5. Will RG. Subacute spongiform encephalopathies. In: Current Medicine 3, Ed. D.H. Lawson, Published: Churchill Livingstone, Edinburgh. 1991; Chapter 9 pp 127-143.
6. Will RG. Comment: Slow virus infection of the central nervous system. Current Medical Literature (Neurology), 1991 Volume 7, Number 3, September 1991, pp 67-69.
7. Will RG. An overview of Creutzfeldt-Jakob disease associated with the use of human pituitary growth hormone. Develop. Biol. Standard 1991; Vol 75: 85-86.
8. Will RG. Epidemiological surveillance of Creutzfeldt-Jakob disease in the United Kingdom. Eur. J. Epidemiol. 1991; 7(5): 460-465.
9. Will RG. The spongiform encephalopathies. JNNP 1991; 54(9): 761-763.

1992

10. Bell JE, Ironside JW, McCardle L & Will RG. Creutzfeldt-Jakob disease - UK Neuropathology Project. Neuropathology and Applied Neurobiology 1992; 18: 302.

11. Brown P, Preece MA, Will RG. 'Friendly fire' in medicine: hormones, homografts and Creutzfeldt-Jakob disease. *Lancet* 1992; 340: 24-27.
12. Esmonde TFG, Will RG. Magnetic resonance imaging in Creutzfeldt-Jakob disease. *Ann. Neurol.* 1992; 31(2): 230.
13. Esmonde TFG, Will RG. Transmissible Spongiform Encephalopathies and their Relationship to Human Neurodegenerative Disease. *British Journal of Hospital Medicine* 1992; 49(6): 400-404.
14. Esmonde TFG, Will RG. Creutzfeldt-Jakob disease in Scotland and Northern Ireland 1980-1989. *Scottish Medical Journal* 1992; 37: 181-184.
15. Ironside JW, Bell JE, McCardle L & Will RG. Neuronal and glial reactions in Creutzfeldt-Jakob Disease. *Neuropathology and Applied Neurobiology* 1992; 18: 295.
16. Ironside JW, Bell JE, Hayward P. Glial and neuronal reactions in Creutzfeldt-Jakob disease. *Clinical Neuropathology* 1992; ii: pp226.
17. Will RG, Esmonde TFG, Matthews WB. Creutzfeldt-Jakob Disease Epidemiology. In: *Prion Diseases of Humans and Animals*. Eds: Prusiner SB, Collinge J, Powell J, Anderton B. 1992; pp 188-199.
18. Will RG. BSE and the spongiform encephalopathies. In: *Recent Advances in Clinical Neurology*. Ed: Kennard C. 1992; Chapter 5, pp 115-127.
19. Will RG, Ironside JW, Bell JE. Bovine spongiform Encephalopathy and risk to health. *BMJ* 1992; 305: 53.
20. Will RG. Prions in animals. *Virus and Life* 1992; 4: 6--8.

1993

21. Bell JE, Ironside JW. How to tackle a possible CJD necropsy. *J Clin Path* 1993; 46: 193-197.
22. Bell JE, Ironside JW. Neuropathology of spongiform encephalopathies in humans. *British Medical Bulletin* 1993; 49: 738-777.
23. Esmonde TFG, Lueck CJ, Symon L, Duchon LW, Will RG. Creutzfeldt-Jakob Disease and Lyophilised Dura Mater Grafts: Report of Two Cases and a Review of the Literature. *JNNP* 1993; 56: 999-1000.
24. Esmonde TFG, Will RG, Slattery JM, Knight R, Harries-Jones R, de Silva R, Matthews WB. Creutzfeldt-Jakob Disease and Blood Transfusion. *Lancet* 1993; 341: 205-207.

25. Ironside JW, McCardle L, Hayward P & Bell JE. Ubiquitin immunocytochemistry in human spongiform encephalopathies. *Neuropathology and Applied Neurobiology* 1993; 19: 134-140.
26. Ironside JW, Barrie C, McCardle L & Bell JE. Microglial cell reactions in human spongiform encephalopathies. *Neuropathology & Applied Neurobiology* 1993; 19(2): 57.
27. Prion Protein: Distribution and Significance in Creutzfeldt-Jakob disease - Thesis submission by Philip Hayward for Degree of Honours BSc (Medical Science) in Department of Pathology.
28. Sawcer SJ, Yuill GM, Esmonde TFG, Estibeiro P, Ironside JW, Bell JE, Will RG. Creutzfeldt-Jakob disease in an individual occupationally exposed to BSE. *Lancet* 1993; 341: 642.
29. The Morphology, Distribution and Cellular Reactions to Amyloid Plaques in Neurodegenerative Diseases and the Aged Brain. Thesis submission to Edinburgh University by Christopher Turner for the degree of BSc (Hons) (Med Sci) in the Department of Pathology, Session 1992-1993.
30. Turner C, Bell JE, Ironside JW. Localisation of microglia in CNS amyloid plaques: an immunocytochemical and confocal microscopic study. *J Pathol* 1993; 170: 401A.
31. Will RG. Abstract: Prion Diseases in Man. 8th Wye College Neuropathology Symposium, 5-9 July 1993.
32. Will RG. Epidemiology of Creutzfeldt-Jakob disease. *British Medical Bulletin* 1993; 49: 960-971.
33. Will RG. The surveillance of Creutzfeldt-Jakob disease in the United Kingdom. In: *Transmissible Spongiform Encephalopathies. Proceedings of a Consultation on BSE with the Scientific Veterinary Committee of the European Communities held in Brussels 14-15 September 1993.* Eds: Bradley R & Marchant B. pp 143.

1994

34. Advisory Committee on Dangerous Pathogens. Precautions for work with human and animal transmissible spongiform encephalopathies. HMSO 1994 (ISBN 0 11 321805 2).
35. Alperovitch A, Brown P, Weber T, Pocchiari M, Hofman A and Will R. Incidence of Creutzfeldt-Jakob disease in Europe in 1993 (Letter). *Lancet* 1994; 343: 918.
36. Brown P, Cervenakova L, Goldfarb L, McCombie WR, Rubenstein R, Will RG, Pocchiari M, Martinez-Lage JF, Scalici C, Masullo C, Graupera G, Ligan J, Gajdusek DC. Iatrogenic Creutzfeldt-Jakob disease: an example of the interplay between ancient genes and modern medicine. *Neurology* 1994; 44: 291-293.

37. Brown P, Kenney K, Little B, Ironside JW, Safar J, Rohwer R, Roos R, Wollmann R, Gibbs CJ Jr, Gajdusek DC. Comparison of clinical features, neuropathology and intracerebral distribution of PrP amyloid protein in the brains of patients with spongiform encephalopathy. *Neurobiol Aging* 1994; 15 (Suppl 1): S150.
38. de Silva R, Esmonde TFG. Iatrogenic transmission of Creutzfeldt-Jakob disease: an update. *CNS Drugs* 1994; 2(2): 96-101.
39. de Silva R, Ironside JW, Barrie C, Esmonde TFG, Bell JE, Will RG. Amyloid plaques in Creutzfeldt-Jakob disease: prevalence and clinical correlates. *Ann Neurol* 1994; 36(2): 273.
40. de Silva R, Ironside JW, McCardle L, Esmonde T, Bell J, Will R, Windl O, Dempster M, Esitbeiro P, Lathe R. Neuropathological phenotype and "prion protein" genotype correlation in sporadic Creutzfeldt-Jakob disease. *Neuroscience Letters* 1994; 179: 50-52.
41. de Silva R, Windl O, Dempster M, Esitbeiro P, Esmonde TFG, Lathe R, Ironside JW, Will RG. Prion protein genotype in Creutzfeldt-Jakob disease: the Edinburgh experience. *Ann Neurol* 1994; 36(2): 272.
42. Esmonde TFG, Will RG, Ironside J, Cousens S. Creutzfeldt-Jakob disease: a case-control study. *Neurology* 1994; 44 (Suppl 2): A193.
43. Gray F, Chretien F, Cesaro P, Chatelain J, Beaudry P, Laplanche JL, Mikol J, Bell J, Gambetti P, Degos JD. Creutzfeldt-Jakob disease and cerebral amyloid angiopathy. *Acta Neuropathol* 1994; 88: 106-111.
44. Hayward PAR, Bell JE, Ironside JW. Prion protein immunocytochemistry: reliable protocols for the investigation of Creutzfeldt-Jakob disease. *Neuropathology and Applied Neurobiology* 1994; 20: 375-383.
45. Ironside JW, DeArmond SJ. Human prion diseases (Workshop 4). *Brain Pathol* 1994; 4: 313-315.
46. McNaughton H, Will RG. Creutzfeldt-Jakob disease presenting as stroke: an analysis of 30 cases. *Ann Neurol* 1994; 36(2):313.
47. Prion Protein Pathology in Sporadic Creutzfeldt-Jakob Disease. Thesis submission to Edinburgh University by Simon Thomas MacDonald for the degree of BSc (Hons) (Med Sci) in the Department of Pathology 1994.
48. Sutherland K, Barrie C and Ironside JW. Automatic quantification of amyloid plaque formation in human spongiform encephalopathy. *Neurodegeneration* 1994; 3: 293-300.
49. Sutherland K, Barrie C, Ironside JW. Automatic image analysis of PrP plaque formation in human spongiform encephalopathy. *Neuropathology and Applied Neurobiology* 1994; 20: 518.

50. Sutherland K, Ironside JW. Novel application of image analysis to the detection of spongiform change. *Analytical and Quantitative Cytology and Histology* 1994; 16(6): 430-434.
 51. Sutherland K, Rutovitz D, Bell JE, Ironside JW. Evaluation of a novel application of image analysis to spongiform change detection. *Proceedings of the IEEE International Conference in Imaging Processing*, Austin TX, November 1994, pp 378-381.
 52. Tobias E, Mann C, Bone I, de Silva R, Ironside JW. A case of Creutzfeldt-Jakob disease presenting with cortical deafness (Letter). *JNNP* 1994; 57(7): 872-873.
 53. Wientjens DPWM, Will RG, Hofman A. Creutzfeldt-Jakob disease: a collaborative study in Europe. *JNNP* 1994; 57: 1285-1299.
 54. Will RG and Wilesmith JW. Response to the article: "Vertical transfer of prion disease" by Lacey and Dealler. *Human Reproduction* 1994; 9(10): 1792-1800.
 55. Will RG. Commentary: Gene influences of Creutzfeldt-Jakob disease. *Lancet* 1994; 344: 1310-1311.
 56. Will RG. The United Kingdom and European CJD Surveillance System. Highlights and Developments. Abstract presented at OIE meeting in Paris 1-2 September 1994.
- 1995
57. Bateman D, Hilton D, Love S, Zeidler M, Beck J, Collinge J. Sporadic Creutzfeldt-Jakob disease in a 18-year old in the UK. *Lancet* 1995; 346:1155-1156.
 58. Brown P, Kenney K, Little B, Ironside J, Will R, Cervenakova L, Bjork RJ, San Martin RA, Safar J, Roos R, Haltia M, Gibbs CJ Jr, Gajdusek DC. Intracerebral distribution of infectious amyloid protein in spongiform encephalopathy. *Ann Neurol* 1995; 38: 245-253.
 59. Budka H, Aguzzi A, Brown P, Brucher JM, Bugiani O, Collinge J, Diringer H, Gullotta F, Haltia M, Hauw JJ, Ironside JW, Kretzschmar HA, Lantos PL, Masullo C, Pocchiari M, Schlote W, Tateishi J, Will RG. Tissue Handling in Suspected Creutzfeldt-Jakob Disease (CJD) and Other Human Spongiform Encephalopathies (Prion Diseases). *Brain Pathology* 1995; 5:319-322.
 60. Budka H, Aguzzi A, Brown P, Brucher JM, Bugiani O, Gullotta F, Haltia M, Hauw J-J, Ironside JW, Jellinger K, Kretzschmar HA, Lantos PL, Masullo C, Schlote W, Tateishi J, Weller RO. Neuropathological Diagnostic Criteria for Creutzfeldt-Jakob Disease (CJD) and Other Human Spongiform Encephalopathies (Prion Diseases). *Brain Pathology* 1995; 5: 459-466.
 61. Collinge J, Palmer MS, Sidle KCL, Gowland I, Medori R, Ironside J, Lantos P. Transmission of fatal familial insomnia to laboratory animals. *Lancet* 1995; 346: 569-570.

62. Delasnerie-Laupretre N, Poser S, Pocchiari M, Wientjens DPWM, Will RG. Creutzfeldt-Jakob disease in Europe. *Lancet* 1995; 346:898.
63. Goodbrand IA, Ironside JW, Nicolson D, Bell JE. Prion protein accumulation in the spinal cords of patients with sporadic and growth hormone associated Creutzfeldt-Jakob disease. *Neuroscience Letters* 1995; 183: 127-130.
64. Goodbrand IA, Nicolson D, Bell JE, Ironside JW. Prion protein localization in the spinal cord and brain stem in iatrogenic and sporadic CJD: an immunocytochemical study with pathogenetic implications. *Neuropathology and Applied Neurobiology* 1995; 21: 444.
65. Ironside JW, Bell JE. PrP immunocytochemistry in sporadic and iatrogenic CJD. *Clinical Neuroscience* 1995; 48(Suppl): 43.
66. Jeffrey M, Goodbrand IA, Goodsir CM. Pathology of the transmissible spongiform encephalopathies with special emphasis on ultrastructure. *Micron* 1995; 26(3): 277-298.
67. Nicholl D, Windl O, de Silva R, Sawcer S, Dempster M, Ironside JW, Estibeiro JP, Yuill GM, Lathe R, Will RG. Inherited Creutzfeldt-Jakob disease in a British family associated with a novel 144 base pair insertion of the prion protein gene. *JNNP* 1995; 58: 65-69.
68. Pickering-Brown SM, Mann DMA, Owen F, Ironside JW, de Silva R, Roberts DA, Balderson, Cooper PN. Allelic variations in apolipoprotein E and prion protein genotype related to plaque formation and age of onset in sporadic Creutzfeldt-Jakob disease. *Neuroscience Letters* 1995; 187: 127-129.
69. Revesz T, Daniel SE, Lees AJ, Will RG. A case of progressive subcortical gliosis associated with deposition of abnormal prion protein (PrP). *JNNP* 1995; 58: 759-760.
70. Smith PEM, Zeidler M, Ironside JW, Estibeiro P, Moss TH. Creutzfeldt-Jakob disease in a dairy farmer. *Lancet* 1995; 346:898.
71. Surveillance of Creutzfeldt-Jakob Disease. Thesis submission by Dr T.F.G. Esmonde to Trinity College, University of Dublin, June 1995. Degree of MD awarded.
72. Sutherland K, Macdonald ST, Barrie C, Ironside JW. Assessment of neuropathological targeting in Creutzfeldt-Jakob disease: a quantitative immunocytochemical study. *Neuropathology and Applied Neurobiology* 1995; 15.
73. Will RG. Creutzfeldt-Jakob disease. *Postgraduate Doctor Middle East* 1995; 18: 177-182.
74. Will RG. Possible Creutzfeldt-Jakob disease in an adolescent. *World Health Organisation Weekly Epidemiological Record* 1995; 15: 105-106.
75. Will RG. Commentary: Scrapie revisited. *BMJ* 1995; 311:1075-1076.

76. Will RG. Creutzfeldt-Jakob disease. *Postgraduate Doctor Caribbean* 1995; 11: 50-56.

1996

77. An investigation into the use of PrP immunostaining in a dedicated laboratory for human spongiform encephalopathies. Thesis submission from Mrs L. McCardle for Fellowship of the Institute of Biomedical Scientists, London. Awarded May 1996.
78. Baker HF, Ridley RM, Wells GA, Ironside JW. Spontaneous spongiform encephalopathy in a monkey. *Lancet* 1996; 348: 955-956.
79. Campbell TA, Palmer MS, Will RG, Gibb WRG, Luthert PJ, Collinge J. A prion disease with a novel 96-base pair insertional mutation in the prion protein gene. *Neurology* 1996; 46:761-766.
80. Collinge J, Beck J, Campbell T, Estibeiro K, Will RG. Prion protein gene analysis in new variant cases of Creutzfeldt-Jakob disease. *Lancet* 1996; 348:56.
81. Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. *Nature* 1996; 383: 685-690.
82. Holmes SJ, Ironside JW, Shalet SM. Neurosurgery in a patient with Creutzfeldt-Jakob disease after pituitary derived growth hormone therapy in childhood. *JNNP* 1996; 60(3): 333-335.
83. Ironside JW. Neuropathological diagnosis of human prion disease: morphological studies. In: Baker H, Ridley RM, eds. *Methods in Molecular Medicine: Prion Diseases*. Totowa, NJ: Humana Press Inc, 1996:35-57.
84. Ironside JW, Bell JE. The 'high-risk' neuropathological autopsy in AIDS and Creutzfeldt-Jakob disease: principles and practice. *Neuropathology and Applied Neurobiology* 1996; 22: 388-393.
85. Ironside JW. Prion diseases: epidemiology and pathology. *Neuropathology and Applied Neurobiology* 1996; 22: 173-175.
86. Ironside JW, Sutherland K, Bell JE, McCardle L, Barrie C, Estibeiro K, Zeidler M, Will RG. A new variant of Creutzfeldt-Jakob disease: neuropathological and clinical features. *Cold Spring Harbour Symposia on Quantitative Biology* 1996; LXI: 523-530.
87. Ironside JW. Prion diseases: update on Creutzfeldt-Jakob disease. *Neuropathology and Applied Neurobiology* 1996; 22: 446.
88. Ironside JW, Goodbrand IA, Bell JE, Will RG. PrP accumulation in sporadic and iatrogenic CJD. *Neuropathology and Applied Neurobiology* 1996; 22: 7.
89. Ironside JW. Human prion diseases. *J Neural Transm* 1996; 47 (Suppl): 231-246.
90. Ironside JW. Review: Creutzfeldt-Jakob disease. *Brain Pathol* 1996; 6: 379-388.

91. Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. *Arch Neurol* 1996; 53: 913-920.
92. Lasmézas GI, Deslys J-P, Demaimay R, Adjou KT, Lamoury F, Dormont D, Robain O, Ironside J, Hauw J-J. BSE transmission to macaques. *Nature* 1996; 381: 743-744.
93. MacDonald ST, Sutherland K, Ironside JW. A quantitative and qualitative analysis of prion protein immunohistochemical staining in Creutzfeldt-Jakob disease using four anti prion protein antibodies. *Neurodegeneration* 1996; 5: 87-94.
94. MacDonald ST, Sutherland K, Ironside JW. Prion protein genotype and pathological phenotype studies in sporadic Creutzfeldt-Jakob disease. *Neuropathology and Applied Neurobiology* 1996; 22: 285-292.
95. Peet R, Sutherland K, Ironside JW. Quantitative methods in the analysis of a new variant of Creutzfeldt-Jakob disease. *Electronic Journal of Pathology and Histology* 1996; 2: 964-967.
96. Roos RAC, Wintzen AR, Will RG, Ironside JW, van Duinen SG. Een patient met de ziekte van Creutzfeldt-Jakob na behandeling met humaan groeihormoon. *Ned Tijdschr Geneesk* 1996; 40(22):1190-1193.
97. Sutherland K, Goodbrand IA, Bell JE, Ironside JW. Objective quantification of prion protein in spinal cords of cases of Creutzfeldt-Jakob disease. *Analytical Cellular Pathology* 1996; 10: 25-35.
98. Sutherland K, Ironside JW. Quantifying spongiform change in the brain by image analysis. *Microscopy & Analysis, January* 1996: 15-16.
99. Sutherland K, Macdonald S, Ironside JW. Quantification and analysis of the neuropathological features of Creutzfeldt-Jakob disease. *Journal of Neuroscience Methods* 1996; 64: 123-132.
100. Sutherland K, Ironside JW. Automatic quantification of astrocyte numbers in Creutzfeldt-Jakob disease. *Neuropathology and Applied Neurobiology* 1996; 22: 7.
101. Sutherland K, Ironside JW. Automatic computerised image analysis of neuropathology in Creutzfeldt-Jakob disease. In: *Transmissible Subacute Spongiform Encephalopathies: Prion Diseases*, Eds: Court L., Dodet B., Elsevier, Paris 1996: 89-95.
102. Wientjens DPWM, Davanipour Z, Hofman A, Kondo K, Matthews WB, Will RG, van Duijn CM. Risk factors for Creutzfeldt-Jakob disease: a re-analysis of case-control studies. *Neurology* 1996; 46:1287-1291.
103. Wientjens,D.P.W.M., Delasnerie-Laupretre,N., Hofman,A., Poser,S., Pocchiari,M. and Will,R.G. Incidence of Creutzfeldt-Jakob disease in Europe. *Neurology* 1996; 46: A290.

104. Will RG, Ironside JW, Hornlimann B, Zeidler M. Creutzfeldt-Jakob disease (Letter). *Lancet* 1996; 347:65-66.
105. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG. A new variant of Creutzfeldt-Jakob disease in the UK. *Lancet* 1996; 347:921-925.
106. Will RG, Zeidler M, Brown P, Harrington MG, Lee KH, Kenney KL. Cerebrospinal fluid test for new variant Creutzfeldt-Jakob disease. *Lancet* 1996; 348:955-956.
107. Will RG, Zeidler M. Diagnosing Creutzfeldt-Jakob disease. *BMJ* 1996; 313:833-834.
108. Will RG. Incidence of Creutzfeldt-Jakob disease in the European Community. In: Gibbs C.J. Jr, ed. *Bovine Spongiform Encephalopathy: The BSE Dilemma*, Springer-Verlag New York Inc, 1996; Chapter 27, pp 364-374.
109. Will RG. Surveillance of Prion Diseases in Humans. In: Baker H, Ridley RM, eds. *Methods in Molecular Medicine: Prion Diseases*. Totowa, NJ: Humana Press Inc, 1996:119-137.
110. Will RG. Surveillance of Creutzfeldt-Jakob disease. *Science in Parliament* 1996; 53(6): 4-5.
111. Will RG. Are prions relevant to transfusion? *Transfusion Medicine* 1996; 6(Suppl 2): 1.
112. Windl O, Dempster M, Estibeiro JP, Lathe R, de Silva R, Esmonde T, Will R, Springbett A, Campbell TA, Sidle KCL, Palmer MS, Collinge J. Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene. *Hum Genet* 1996; 98:259-264.
113. Young GR, Fletcher NA, Zeidler M, Estibeiro KL, Ironside JW. Creutzfeldt-Jakob disease in a beef farmer. *Lancet* 1996; 348:610-611.
114. Zeidler M, Will RG, Ironside JW, Sellar R, Wardlaw J. Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Magnetic resonance imaging is not a sensitive test for CJD (Letter). *BMJ* 1996; 312: 844.

1997

115. Bell JE, Ironside JW. Principles and practice of "high-risk" brain banking. *Neuropathology and Applied Neurobiology* 1997; 23: 281-288.
116. Bell JE, Gentleman SM, Ironside JW, McCardle L, Lantos PL, Doey L, Lowe J, Fergusson J, Luthert P, McQuaid S. Prion protein immunocytochemistry - UK five centre consensus report. *Neuropathology and Applied Neurobiology* 1997; 23: 26-35.

117. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCordle L, Chree A, Hope J, Birkett C, Cousens S, Freaser H, Bostock CJ. Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent. *Nature* 1997; 389: 498-501.
118. Cousens,SN, Vynnycky E, Zeidler M, Will RG and Smith PG. Predicting the CJD epidemic in humans. *Nature* 1997; 385:197-198.
119. Cousens SN, Zeidler M, Esmonde TF, De Silva R, Wilesmith JW, Smith PG, Will RG. Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96. *BMJ* 1997; 315: 389-395.
120. De Silva R, Findlay C, Awad I, Harries-Jones R, Knight R, Will R. Creutzfeldt-Jakob disease in the elderly. *Postgrad Med J* 1997; 73: 557-559.
121. Diringer H, Beekes M, Ozel M, Simon D, Queck I, Cardone F, Pocchiari M, Ironside JW. Highly infectious purified preparations of disease-specific amyloid of transmissible spongiform encephalopathies are not devoid of nucleic acids of viral size. *Intervirology* 1997; 40: 238-46.
122. Hill AF, Zeidler M, Ironside J, Collinge J. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. *Lancet* 1997; 349: 99-100.
123. Hill AF, Will RG, Ironside J, Collinge J. Type of prion protein in UK farmers with Creutzfeldt-Jakob disease. *Lancet* 1997; 350: 188.
124. Ironside JW , Bell JE. Pathology of Prion Diseases. In: Collinge J , Palmer MS. (Eds.) *Prion Diseases*, 1997 pp. 25-50. Oxford:Oxford University Press.
125. Ironside JW. Transmissible Spongiform Encephalopathies. In: Greenwood D, Slack RCB, Peutherer JF. (Eds.) *Medical Microbiology*, 1997 15th edn. pp. 548-555. Edinburgh:Churchill Livingstone.
126. Ironside JW. New variant Creutzfeldt-Jakob disease in the UK: clinical and pathological studies. *Brain Pathology* 1997; 7: 1243-1245.
127. Ironside JW. Transmissible spongiform encephalopathies: the relationship between Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. *Current Opinion in Infectious Diseases* 1997; 10: 1-14.
128. Ironside JW, Bell JE. Florid plaques and new variant Creutzfeldt-Jakob disease. *Lancet* 1997; 350: 1475.
129. Ironside JW. New variant CJD. In: *Recent Advances in Histopathology*. Eds: Lowe D, Underwood JCE, Churchill Livingstone, Edinburgh 1997: 944.
130. Ironside JW. General features of prion diseases. In: *Clinical and Pathological Basis of Neurodegeneration*. Eds: Trojanowski JQ, Williams and Wilkins, Baltimore 1997: 943.

131. Ironside JW. The new variant form of Creutzfeldt-Jakob disease: a novel prion protein amyloid disorder. *Amyloid* 1997; 4: 66-69.
132. McCardle L. Human prion diseases (Biomedical Comment). *British Journal of Biomedical Science*. 1997; 54: 2-4.
133. McLean CA, Ironside JW, Masters CL. Comparative neuropathology in kuru and new variant CJD. *Brain Pathology* 1997; 7: 1247-1248.
134. McNaughton HK, Will RG. Creutzfeldt-Jakob disease presenting acutely as stroke: an analysis of 30 cases. *Neurological Infections and Epidemiology* 1997; 2: 19-24.
135. Nicoll JA, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, Stewart J, Vinters HV. High frequency of apolipoprotein E epsilon 2 allele in haemorrhage due to cerebral amyloid angiopathy. *Annals of Neurology* 1997; 41: 716-721.
136. Raymond GJ, Hope J, Kocisko DA, Priola SA, Raymond LD, Bossers A, Ironside JW, Will RG, Chen SG, Petersen RB, Gambetti P, Smits A, Rubenstein R, Lansbury Jr PT, Caughey B. Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. *Nature* 1997; 388: 228-229.
137. Sellar RJ, Will RG, Zeidler M. MR imaging of new variant Creutzfeldt-Jakob disease: the pulvinar sign. *Neuroradiology* 1997; 39: S53.
138. Stewart B, Ironside JW, Fraser JR. Quantification of scrapie pathology following infection by the intramuscular, intraperitoneal and oral routes. *Brain Pathology* 1997; 7: 1380.
139. Sutherland K, De Silva R, Will RG. Clinical diagnosis of Creutzfeldt-Jakob disease using a multi-layer perceptron neural network classifier. *Journal of Intelligent Systems* 1997; 7(1-2): 1-18.
140. Whittle IR, Will RG, Ironside JW. Brain biopsy and patients with atypical presentations of sporadic Creutzfeldt-Jakob disease. *JNNP* 1997; 63: 547-558.
141. Will RG, Knight RSG, Zeidler M, Stewart G, Ironside JW, Cousens SN, Smith PG. Reporting of suspect new variant Creutzfeldt-Jakob disease. *Lancet* 1997; 349: 847.
142. Will RG. A new variant of Creutzfeldt-Jakob Disease in the UK. *Society for Veterinary Epidemiology and Preventative Medicine - Proceedings*. 1997; 1-278.
143. Will RG. New variant Creutzfeldt-Jakob disease. *Alzheimer's Review* 1997; 7(1): 145-147.
144. Zeidler M, Johnstone EC, Bamber RWK, Dickens CM, Fisher CJ, Francis AF, Goldbeck R, Higgo R, Johnson-Sabine EC, Lodge GJ, McGarry P, Mitchell S, Tarlo L, Turner M, Ryley P, Will RG. New variant Creutzfeldt-Jakob disease: psychiatric features. *Lancet* 1997; 350: 908-910.

145. Zeidler M, Stewart GE, Barraclough CR, Bateman DE, Bates D, Burn DJ, Colchester AC, Durward W, Fletcher NA, Hawkins SA, Mackenzie JM, Will RG. New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests. *Lancet* 1997; 350: 903-907.
146. Zeidler M, Stewart G, Cousens SN, Estibeiro K, Will RG. Codon129 genotype and new variant CJD. *Lancet* 1997; 350: 668.
147. Zeidler M, Estibeiro K, Will RG. The genetics of Creutzfeldt-Jakob disease in the United Kingdom. *JNNP* 1997; 206.

1998

148. Baker HF, Ridley RM, Wells GAH, Ironside JW. Prion protein immunohistochemical staining in the brains of monkeys with transmissible spongiform encephalopathy. *Neuropathology and Applied Neurobiology* 1998; 24: 476-486.
149. Chamberland ME, Epstein J, Dodd RY, Persing D, Will RG, DeMaria Jr A, Emmanuel JC, Pierce B, Khabbaz R. Blood safety. *Emerging Infectious Diseases* 1998; 4(3): 410-411.
150. Collie DA, Sellar RJ, Ironside J, Zeidler M, Stewart G, Knight R, Will RG. New variant Creutzfeldt-Jakob disease: diagnostic features on MRI with histopathological correlation. *Proceedings of ASNR, AJNR (Suppl)* 1998; 20: 139 (abstract).
151. Dorandeu A, Wingertsman L, Ironside JW, Delisle M-B, Vital C, Parchi P, Montagna P, Lugaresi E, Budka H, Gambetti P, Gray F. Neuronal apoptosis in fatal familial insomnia. *Brain Pathology* 1998; 8: 531-537.
152. Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. *Lancet* 1998; 352: 703-704.
153. Ironside JW. Neuropathological findings in new variant CJD and experimental transmission of BSE. *FEMS Immunology and Medical Microbiology* 1998; 21: 91-95.
154. Ironside JW. The work of the National CJD Surveillance Unit. *ACP News* 1998; 27-29.
155. Ironside JW. Creutzfeldt-Jakob disease - The Story so Far. *Proceedings of the Royal College of Physicians, Edinburgh* 1998; 28: 143-149.
156. Ironside JW, Knight RS, Will RG, Brown PW. New variant Creutzfeldt-Jakob disease is more common in Britain than elsewhere. *BMJ* 1998; 317: 352.
157. Ironside JW. New-variant Creutzfeldt-Jakob disease. *Neuropathology* 1998; 18(2): 131-138.
158. Ironside JW. Prion diseases in man. *J Pathol* 1998 186(3): 227-234.

159. Knight R, Stewart G. The new variant form of Creutzfeldt-Jakob disease. *FEMS Immunology & Medical Microbiology* 1998; 21: 97-100.
160. Knight R. Creutzfeldt-Jakob disease: clinical features, epidemiology and tests. *Electrophoresis* 1998; 19: 1306-1310.
161. Knight RSG. The diagnosis of prion diseases. *Parasitology* 1998; 117: S3-S11.
162. Lee CA, Ironside JW, Bell JE, Giangrande P, Ludlam C, Esiri MM, McLaughlin JE. Retrospective neuropathological review of prion disease in UK haemophilic patients. *Thromb Haemost* 1998; 80(6): 909-11.
163. McLean CA, Ironside JW, Alpers MP, Brown PW, Cervenakova L, Anderson RMcD, Masters CL. Comparative neuropathology of kuru with the new variant of Creutzfeldt-Jakob disease: evidence for strain of agent predominating over genotype host. *Brain Pathology* 1998; 8: 429-437.
164. Nailon WH, Ironside JW. Image processing in neuropathology. In: *Proceedings of the Second Workshop on Advances in Brain Morphometry*, Leeds Castle, Kent, 24-26th October 1998.
165. Piccardo P, Dlouhy SR, Lievens PMJ, Young K, Bird DPTD, Nochlin D, Dickson DW, Vinters HV, Zimmerman TR, Mackenzie IRA, Kish SJ, Ang L-C, de Carli C, Pocchiari M, Brown P, Gibbs Jr. CJ, Gajdusek DC, Bugiani O, Ironside J, Tagliavini F, Ghetti B. Phenotypic variability of Gerstmann-Straussler-Scheinker disease is associated with prion protein heterogeneity. *J Neuropathol Exp Neurol* 1998; 57(10): 979-988.
166. Schultz DW, Lennox GG, Ironside JW, Warlow CP. Behavioural disturbance and visual hallucinations in a 78 year old man. *JNNP* 1998; 65(6): 933-8.
167. Stewart GE, Ironside JW. New variant Creutzfeldt-Jakob disease. *Current Opinion in Neurology* 1998; 11: 259-262.
168. van Duijn CM, Delasnerie-Laupretre N, Masullo C, Zerr I, De Silva R, Wientjens DPWM, Brandel J-P, Weber T, Bonavita V, Zeidler M, Alperovitch A, Poser S, Granieri E, Hofman A, Will RG. Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. *Lancet* 1998; 351: 1081-1085.
169. Will RG, Campbell MJ, Moss TH, Bell JE, Ironside JW. FFI cases from the United Kingdom. *Brain Pathology* 1998; 8: 563.
170. Will R. New variant Creutzfeldt-Jakob disease. In: Morrison D. ed. *Prions and Brain Diseases in Animals and Humans*. New York: Plenum Press, 1998:141-145.
171. Will RG. New Variant Creutzfeldt-Jakob Disease. *The Darlington Postgraduate Journal* 1998; 17(1): 35-42.
172. Will RG. Transmissible spongiform encephalopathy: BSE/CJD - the new variant CJD. In: Goebel K, ed. *The Science and Culture Series: Nuclear Strategy and Peace Technology*. International Seminar on nuclear war and planetary emergencies. Singapore: World Scientific Publishing Co. Pte. Ltd, 1998: 133-134.


173. Will RG. Update on surveillance of Creutzfeldt-Jakob disease in Europe. In: Office International des Epizooties, ed. Epidemiological studies and research on transmissible spongiform encephalopathies. Paris: Office International des Epizooties, 1998: 10-12.
174. Will RG. New variant Creutzfeldt-Jakob disease. In: Brown F, Griffiths E, Horaud F, Petricciani JC, eds. Safety of Biological Products prepared from Mammalian Cell Culture. Basel: Karger. 1998: 79-84.
175. Will RG, Alperovitch A, Poser S, Pocchiari M, Hofman A, Mitrova E, De Silva R, D'Alessandro M, Delasnerie-Laupretre N, Zerr I, van Duijn C. Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993-1995. *Ann Neurol* 1998; 43: 763-767.
176. Will RG, Kimberlin RH. Creutzfeldt-Jakob disease and the risk from blood or blood products. *Vox Sang* 1998; 75: 178-180.
177. Will RG. Epidemiology and Creutzfeldt-Jakob disease. In: Sterilization of Medical Products. Eds: R.F. Morrissey, JB Kowalski. Polyscience Publications Inc., Champlain, N.Y. pp 202-211.
178. Zeidler M, Will RG, Ironside JW, Sellar R, Wardlaw J. Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Magnetic resonance imaging is not a sensitive test for Creutzfeldt-Jakob disease. *British Medical Journal* 1998; 312: 844.

1999

179. Alperovitch A, Zerr I, Pocchiari M, Mitrova E, de Pedro Cuesta J, Hegyi I, Collins S, Kretschmar H, van Duijn C, Will RG. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. *Lancet* 1999; 353: 1673-1674.
180. Bruce ME, Will RG, Ironside JW, Fraser H. Comparison of the biological characteristics of BSE and CJD in mice. In: Alzheimer's Disease and Related Disorders Eds: Iqbal K, Swaab DF, Winblad B, Wisniewski HM. John Wiley, London, 1999: 553-560.
181. Churchill D, Churchill DJ, Will RG. Organophosphate exposure and variant Creutzfeldt-Jakob disease. *Lancet* 1999; 353: 1410.
182. Cousens SN, Linsell L, Smith PG, Chandrakumar M, Wilesmith JW, Knight RSG, Zeidler M, Stewart G, Will RG. Geographical distribution of variant CJD in the UK (excluding Northern Ireland). *Lancet* 1999; 353: 18-21.
183. Gray F, Chretien F, Adle-Biassette H, Dorandeu A, Ereau T, Delisle M-B, Kopp N, Ironside JW, Vital C. Neuronal apoptosis in Creutzfeldt-Jakob disease. *Journal of Neuropathology and Experimental Neurology* 1999; 58: 321-328.
184. Greene JD, Hedges JR, Ironside JW, Warlow CP. Progressive aphasia with rapidly progressive dementia in a 49 year old woman. *JNNP* 1999; 66: 238-243.

185. Hill AF, Butterworth RJ, Joiner S, Jackson G, Rossor MN, Thomas DJ, Frosh A, Tolley N, Bell JE, Spencer M, King A, Al-Sarraj S, Ironside JW, Lantos PL, Collinge J. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. *Lancet* 1999; 353: 183-189.
186. Ironside JW. New variant Creutzfeldt-Jakob disease. In: *Recent Advances in Histopathology* eds: Lowe DG, Underwood JCE. Churchill Livingstone, Edinburgh. 1999: 1-22.
187. Ironside JW. nvCJD: exploring the limits of our understanding. *Biologist* 1999; 46: 172-176.
188. Knight R. The relationship between new variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. *Vox Sanguinis* 1999; 76: 203-208.
189. Macleod MA, Knight RSG. New variant Creutzfeldt-Jakob disease. *Cattle Practice* 1999; 7(2): 211-214.
190. Macleod MA, Knight R, Stewart G, Zeidler M, Will R. Clinical features of nvCJD. *European Journal of Neurology* 1999; 6(3): 26-27 (abstract).
191. Mallucci GR, Campbell TA, Dickinson A, Beck J, Holt M, Plant G et al. Inherited prion diseases with alanine to valine mutation at codon 117 in the prion protein gene. *Brain* 1999; 122: 1823-1837.
192. Manson JC, Jamieson E, Baybutt H, Tuzi NL, Barron R, McConnell I et al. A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. *The EMBO Journal* 1999; 18: 6855-6864.
193. Nailon WH, Ironside JW. Creutzfeldt-Jakob disease - statistical texture analysis of abnormal prion protein. In: *Proceedings of the first joint meeting of the Biomedical Engineering Society (BMES) and the 21st Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS)*, Atlanta, Georgia, 13-16 October 1999.
194. Nailon WH, Ironside JW. Quantitative image analysis of thalamic pathology in new variant Creutzfeldt-Jakob disease. In: *Proceedings of Medical Image Understanding and Analysis (MIUA'99)*, Examinations School, Oxford, 19-20th July 1999.
195. Richard M, Biacabe AG, Perret-Liaudet A, McCardle L, Ironside JW, Kopp N. Protection of personnel and environment against Creutzfeldt-Jakob disease in pathology laboratories. *Clinical Experimental Pathology* 1999; 47: 192-200.
196. Scott MR, Will RG, Ironside J, Nguyen H-OB, Tremblay P, DeArmond SJ, Prusiner SB. Compelling transgenic evidence for transmission of bovine spongiform encephalopathy prions to humans. *PNAS* 1999; 96(26): 15137-15142.
197. Shimizu S, Hoshi K, Muramoto T, Homma M, Ironside JW, Kuzuhara S, Sato T, Yamamoto T, Kitamoto T. Creutzfeldt-Jakob disease with florid-type plaques after cadaveric dura mater grafting. *Arch Neurol* 1999; 36: 357-362.

198. Turner ML, Ironside JW. New variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion. *Blood Reviews* 1999; 12: 255-268.
199. Will RG, Alpers MP, Dormont D, Schonberger LB, Tateishi J. Infectious and sporadic prion diseases. In: *Prion Biology and Diseases*. Ed: Prusiner SB. Cold Spring Harbour Laboratory Press, New York. 1999; pp 465-507.
200. Will RG, Cousens SN, Farrington CP, Smith PG, Knight RSG, Ironside JW. Deaths from variant Creutzfeldt-Jakob disease. *Lancet* 1999; 353: 979.
201. Will RG, Ironside JW. Commentary: Oral infection by the bovine spongiform encephalopathy prion. *PNAS* 1999; 96: 4738-4739.
202. Will RG, Stewart G, Zeidler M, Macleod MA, Knight RSG. Psychiatric features of new variant Creutzfeldt-Jakob disease. *Psychiatric Bulletin* 1999; 23: 264-267.
203. Will RG. Classical CJD is not forgotten. *CJD Support Network Newsletter* 1999; 6-7.
204. Will RG. New variant Creutzfeldt-Jakob disease. *Biomed & Pharmacother* 1999; 53: 9-13.
205. Will RG. Prion related disorders. *J Royal College Physicians London* 1999; 33: 311-315.
206. Will RG. *The relationship between BSE and Creutzfeldt-Jakob disease*. In: *International Seminar on Nuclear War and Planetary Emergencies 23rd Session*. Ed: Goebel K. World Scientific Publishing Co. Pte. Ltd., Singapore. 1999; pp 38-39.
207. Will RG. CJD and blood transfusion. *CJD Support Network Newsletter* 1999; 8-9.
208. Will RG. The transmission of prions to humans. *Acta Paediatr Suppl* 1999; 433: 28-32.
209. Zeidler M, Knight R, Stewart G, Ironside JW, Will RG, Green AJE, Pocchiari M. Diagnosis of Creutzfeldt-Jakob disease. Routine tonsil biopsy for diagnosis of new variant Creutzfeldt-Jakob disease is not justified. *BMJ* 1999; 318: 538-538.



Staff based at CJD Surveillance Unit Western General Hospital, Edinburgh

Professor RG Will
 Dr JW Ironside
 Dr RSG Knight
 Dr JE Bell
 Dr H Ward
 Dr MA Macleod
 Mrs B Bathgate-Smith
 Ms Margaret Leitch*
 Mr G McLean*
 Dr M Bruce*
 Ms J Mackenzie
 Mr A Hunter
 Ms D Everington
 Mr N Attwood
 Mrs L McCardle
 Mrs M Le Grice, Ms S Lowrie and Mrs M Nicol
 Ms D Best, Ms D Auras
 Dr M Head
 Ms BA Mackenzie
 Ms A Honeyman, Mrs S MacDonald
 Mrs M Wells

Staff funded by Other Sources

Dr W. Nailon (BBSRC)
 Dr N McLennan (MRC)
 Ms K Rennison (EC BIOTECH)
 Mr T Bunn (UoE)
 Ms T Lindsay (BIOMED2)
 Mrs C Donaldson (BIOMED2)

Director, National CJD Surveillance Unit
 Reader in Pathology
 Consultant Neurologist
 Consultant Neuropathologist
 Consultant Epidemiologist
 Research Registrar
 Nurse Practitioner
 Research Nurse
 National Care Co-ordinator
 Molecular biologist
 Study Co-Ordinator
 Business Manager
 Statistician
 Database Manager
 Chief MLSO
 Senior MLSOs
 Research Technicians
 Research Scientist (molecular and cell biology)
 Neuropathology Database Manager/Secretariat
 Secretariat
 Secretariat - Case-control study

Research Scientist (image analysis)
 Research Scientist (molecular and cell biology)
 Research Technician
 PhD student
 European Study Co-Ordinator
 Secretariat

Epidemiological and Statistical Support London School of Hygiene and Tropical Medicine

Professor P Smith
 Mr S Cousens

Epidemiologist and Head of Dept of Infectious and Tropical Diseases
 Statistician

* started at CJDSU early 2000